Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394511 | 0.92 | TSHR (0.44) | ALDH1A1DGKATSHREPHX2CA1 | |
| SCHEMBL1003368 | 0.92 | CES1 (0.46) | ALDH1A1DGKACES1CES2TSHR | |
| Hydrochloric Acid SCHEMBL27410812 | 0.90 | CES1 (0.44) | ALDH1A1DGKACES1CES2TSHR | |
| Hydrazine SCHEMBL27464055 | 0.88 | CES1 (0.42) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL522691 | 0.85 | DGKA (0.54) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL1639757 | 0.85 | TSHR (0.50) | DGKATSHREPHX2CA1 | |
| SCHEMBL7771101 | 0.83 | DGKA (0.57) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL5732818 | 0.83 | DGKA (0.57) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL9985650 | 0.83 | DGKA (0.57) | ALDH1A1DGKACES1CES2TSHR | |
| SCHEMBL3662225 | 0.83 | DGKA (0.57) | ALDH1A1DGKACES1CES2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9245290-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-01-09 | — | — | US | disclosed |
| US-8518942-B2 | Caspase inhibitors and uses thereof | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110230527-A1 | CASPASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2011-09-22 | — | — | US | disclosed |
| WO-2010017408-A1 | CASPASE INHIBITORS AND USES THEREOF | THE BUCK INSTITUTE FOR AGE RESEARCH (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230527-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP6, CASP3, CASP2 | ALDH1A1 4178/4885DGKA 3704/4885CES1 377/4885 |
| US-20140011847-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP6, CASP3, CASP2 | ALDH1A1 4178/4885DGKA 3704/4885CES1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.